Vontobel Holding Ltd. Acquires 58,772 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Vontobel Holding Ltd. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 9.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 687,261 shares of the company's stock after purchasing an additional 58,772 shares during the quarter. Vontobel Holding Ltd. owned about 0.06% of Teva Pharmaceutical Industries worth $15,147,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TEVA. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock worth $621,337,000 after buying an additional 2,204,623 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after buying an additional 569,412 shares in the last quarter. State Street Corp grew its holdings in shares of Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after buying an additional 1,778,268 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3.4% during the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company's stock worth $157,571,000 after buying an additional 291,124 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.30 during mid-day trading on Tuesday, reaching $16.55. The company's stock had a trading volume of 18,068,410 shares, compared to its average volume of 12,933,461. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The stock has a market cap of $18.74 billion, a P/E ratio of -11.41, a PEG ratio of 1.39 and a beta of 0.71. The business has a 50-day simple moving average of $19.93 and a two-hundred day simple moving average of $18.50. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.